Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy NGM Biopharmaceuticals stock | $19.23

Learn how to easily invest in NGM Biopharmaceuticals stock.

NGM Biopharmaceuticals Inc is a biotechnology business based in the US. NGM Biopharmaceuticals shares (NGM) are listed on the NASDAQ and all prices are listed in US Dollars. NGM Biopharmaceuticals employs 210 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in NGM Biopharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NGM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

NGM Biopharmaceuticals stock price (NASDAQ: NGM)

Use our graph to track the performance of NGM stocks over time.

NGM Biopharmaceuticals shares at a glance

Information last updated 2021-10-24.
Latest market close$19.23
52-week range$14.90 - $32.12
50-day moving average $21.54
200-day moving average $22.28
Wall St. target price$34.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.68

Buy NGM Biopharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy NGM Biopharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NGM Biopharmaceuticals price performance over time

Historical closes compared with the close of $19.23 from 2021-10-22

1 week (2021-10-19) -0.57%
1 month (2021-09-24) -13.61%
3 months (2021-07-26) -10.01%
6 months (2021-04-26) -31.03%
1 year (2020-10-23) 12.79%
2 years (2019-10-25) 45.13%
3 years (2018-10-22) N/A
5 years (2016-10-22) N/A

NGM Biopharmaceuticals financials

Revenue TTM $81.6 million
Gross profit TTM $-76,604,000
Return on assets TTM -19.81%
Return on equity TTM -36.19%
Profit margin -149.51%
Book value $4.83
Market capitalisation $1.5 billion

TTM: trailing 12 months

Shorting NGM Biopharmaceuticals shares

There are currently 788,111 NGM Biopharmaceuticals shares held short by investors – that's known as NGM Biopharmaceuticals's "short interest". This figure is 5.8% up from 745,250 last month.

There are a few different ways that this level of interest in shorting NGM Biopharmaceuticals shares can be evaluated.

NGM Biopharmaceuticals's "short interest ratio" (SIR)

NGM Biopharmaceuticals's "short interest ratio" (SIR) is the quantity of NGM Biopharmaceuticals shares currently shorted divided by the average quantity of NGM Biopharmaceuticals shares traded daily (recently around 455555.49132948). NGM Biopharmaceuticals's SIR currently stands at 1.73. In other words for every 100,000 NGM Biopharmaceuticals shares traded daily on the market, roughly 1730 shares are currently held short.

However NGM Biopharmaceuticals's short interest can also be evaluated against the total number of NGM Biopharmaceuticals shares, or, against the total number of tradable NGM Biopharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NGM Biopharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 NGM Biopharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.025% of the tradable shares (for every 100,000 tradable NGM Biopharmaceuticals shares, roughly 25 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NGM Biopharmaceuticals.

Find out more about how you can short NGM Biopharmaceuticals stock.

NGM Biopharmaceuticals share dividends

We're not expecting NGM Biopharmaceuticals to pay a dividend over the next 12 months.

NGM Biopharmaceuticals share price volatility

Over the last 12 months, NGM Biopharmaceuticals's shares have ranged in value from as little as $14.9 up to $32.12. A popular way to gauge a stock's volatility is its "beta".

NGM.US volatility(beta: 1.97)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NGM Biopharmaceuticals's is 1.9674. This would suggest that NGM Biopharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

NGM Biopharmaceuticals overview

NGM Biopharmaceuticals, Inc. , a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trial for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase Ib clinical trials to inhibit growth differentiation factor GDF15 levels on cancer anorexia/cachexia syndrome; NGM621, an antibody in Phase II clinical trials for the treatment of geographic atrophy; and NGM707 and NGM438, which are in preclinical investigational studies for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. ; and a collaboration agreement with Merck & Co. , Inc.

Frequently asked questions

What percentage of NGM Biopharmaceuticals is owned by insiders or institutions?
Currently 24.657% of NGM Biopharmaceuticals shares are held by insiders and 67.689% by institutions.
How many people work for NGM Biopharmaceuticals?
Latest data suggests 210 work at NGM Biopharmaceuticals.
When does the fiscal year end for NGM Biopharmaceuticals?
NGM Biopharmaceuticals's fiscal year ends in December.
Where is NGM Biopharmaceuticals based?
NGM Biopharmaceuticals's address is: 333 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
What is NGM Biopharmaceuticals's ISIN number?
NGM Biopharmaceuticals's international securities identification number is: US62921N1054
What is NGM Biopharmaceuticals's CUSIP number?
NGM Biopharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 62921N105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site